Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States.

Sophia Hatziantoniou Cleo AnastassopoulouGeorge LazarosKonstantinos VasileiouCostas TsioufisAthanassios Tsakris

Published in: Expert review of vaccines (2022)

Understanding the underlying causes of the observed differences could provide guidance for the enhanced quality of mRNA vaccines that would also foster vaccine acceptance.

Keyphrases

coronavirus disease
sars cov
binding protein
adverse drug
quality improvement
respiratory syndrome coronavirus